Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study)

Eur Heart J. 2006 Aug;27(16):1954-64. doi: 10.1093/eurheartj/ehl146. Epub 2006 Jul 17.

Abstract

Aims: Underuse of warfarin for stroke prophylaxis in atrial fibrillation (AF) is extensive and represents a major problem in clinical practice. To identify factors associated with warfarin treatment in eligible AF patients.

Methods and results: The study population consisted of all Swedish resident AF patients at the Stockholm South General Hospital during 2002 (n=2796). Medical records were examined and complemented by data from the Swedish National Hospital Discharge Register. Sixty-eight percent of the patients (1898/2796) had indications, and no apparent contraindications for warfarin treatment. Of these 54% (1029/1898) got warfarin. Factors favouring warfarin treatment after adjustment for other factors were history of ischaemic stroke, an implanted pacemaker, treatment in a cardiology rather than internal medicine ward and valvular defect. Factors associated with a reduced likelihood of warfarin treatment were paroxysmal type of AF and age >80 years. Important risk factors for stroke in AF like heart failure, hypertension, and diabetes did not increase the chances of warfarin treatment.

Conclusion: Risk stratification using known risk factors of stroke seems to affect warfarin treatment only to a minor degree in clinical practice. Undertreatment was particularly common in patients with paroxysmal AF and in patients aged >80 years and calls for improved clinical routines in accordance with international guidelines.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / complications*
  • Cohort Studies
  • Delivery of Health Care / statistics & numerical data*
  • Female
  • Guideline Adherence
  • Humans
  • Male
  • Middle Aged
  • Practice Guidelines as Topic
  • Risk Assessment
  • Risk Factors
  • Stroke / etiology
  • Stroke / prevention & control*
  • Thromboembolism / prevention & control
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Warfarin